NovaVax’s new coronavirus infection (Corona 19 virus) vaccine (NVX-CoV2373) was confirmed to have an 89.3% preventive effect.
NovaVax vaccine, NVX-CoV2373, is a protein vaccine produced through protein recombination technology of the corona 19 virus surface spike protein. It was produced by adding Spike protein mass-produced from insect cells to a saponin-based Matrix-M adjuvant. These protein vaccines can be stored refrigerated at 2~8ºC and can be handled as liquid preparations, so they have the advantage of being easier to distribute than mRNA vaccines such as Pfizer or Moder or vaccine.
In particular, NovaVax vaccine NVX-CoV2373 has been shown to be effective against both the British variant virus and the South African variant virus. This is the first time among the COVID-19 vaccines that both the UK mutant virus and the South African mutant virus have been proven effective.
According to the information released by US pharmaceutical company NovaVax on the 28th (local time), the phase 3 clinical trial conducted in the UK was conducted on 15,000 British individuals aged 18 to 84. Of these, 62 were confirmed to be infected with Corona 19, 56 of them from the placebo group and 6 from the NVX-CoV2373 vaccination group, showing 89.3% of the preventive effect.
In addition, as more than 50% of infected patients are known as UK mutant virus, it is analyzed that 85.6% is effective in preventing UK mutant virus.
In a phase 2b clinical trial conducted in South Africa, NovaVax’s COVID-19 vaccine showed 60% prevention effect.
In a clinical trial conducted on 4,400 people since August last year, 44 people, including 29 placebo groups and 15 NVX-CoV2373 vaccinated groups, were confirmed to be infected with Corona 19, showing 60% prevention effect. As a result of analyzing the gene sequence of 27 out of 44 infected patients, 92.6% of the patients were identified as corona mutant virus from the Republic of South Africa.
In particular, it was found that one-third of patients included in the clinical trial had already been infected with the corona 19 virus, not the mutant virus, because they were already positive for antibodies before participation.
Accordingly, the researchers revealed that the past Corona 19 infection has no effect on preventing mutant virus infection. On the other hand, the researchers explained that the South African mutation has a preventive effect.
Meanwhile, NovaVax said it has already recruited 16,000 subjects for the’PREVENT-19 test’ scheduled to be conducted in the United States and Mexico. However, NovaVax is expected to complete recruitment of 30,000 by mid-February.
“NVX-CoV2373 is the first vaccine that has proven clinically effective in preventing not only COVID-19 but also the rapidly spreading mutant virus in the UK and South Africa.” “There is a potential to play an important role in resolving the global public health crisis, and in the future, we will work with partners, partners, researchers and health authorities around the world to make the vaccine supply possible as soon as possible.”